Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EPS (Weighted Average and Diluted) (2024 - 2026)

Prelude Therapeutics' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.13 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 69.05% to -$0.13 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.0, a 40.83% increase, with the full-year FY2025 number at -$1.29, up 23.21% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.13 in Q1 2026 for Prelude Therapeutics, up from -$0.2 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for PRLD hit a ceiling of -$0.13 in Q1 2026 and a floor of -$0.46 in Q2 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.35 across 3 years, with a median of -$0.41 in 2025.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): changed 0.0% in 2025 and later skyrocketed 69.05% in 2026.
  • Tracing PRLD's EPS (Weighted Average and Diluted) over 3 years: stood at -$0.38 in 2024, then soared by 47.37% to -$0.2 in 2025, then soared by 35.0% to -$0.13 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for PRLD at -$0.13 in Q1 2026, -$0.2 in Q4 2025, and -$0.26 in Q3 2025.